Search research articles
Contact Us
Filters
Showing results (21-30 of 38) with videos related to
Page
of 4
Sort By:
Current Problems in Cancer
|
January 19, 2021
Response to BRAF and MEK1/2 inhibition in a young adult with BRAF V600E mutant epithelioid glioblastoma multiforme: A Case Report and Literature Review
Ashwin Venkatesh, Amol Joshi, Kieren Allinson, et al.
Plos One
|
January 4, 2013
Bin2 is a membrane sculpting N-BAR protein that influences leucocyte podosomes, motility and phagocytosis
María José Sánchez-Barrena, Yvonne Vallis, Menna R Clatworthy, et al.
Trends in Cancer
|
June 5, 2024
Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer
Chris Abbosh, Darren Hodgson, Gary J Doherty, et al.
Journal for Immunotherapy of Cancer
|
May 30, 2025
Differential safety profiles of durvalumab monotherapy and durvalumab in combination with tremelimumab in adult patients with advanced cancers
Claire Morgan, John Kurland, Mayur Patel, et al.
Iscience
|
September 9, 2024
Machine learning modeling of patient health signals informs long-term survival on immune checkpoint inhibitor therapy
Gerald J Sun, Gustavo Arango-Argoty, Gary J Doherty, et al.
British Journal of Clinical Pharmacology
|
November 12, 2025
Population pharmacokinetics and exposure-response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study
Xiaoying Zhao, Junjie Ding, Jiajia Zhao, et al.
Genes & Development
|
August 10, 2017
Lung tumors with distinct p53 mutations respond similarly to p53 targeted therapy but exhibit genotype-specific statin sensitivity
Frances K Turrell, Emma M Kerr, Meiling Gao, et al.
BMC Cancer
|
January 25, 2022
The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy
Nicola A Thompson, Grant D Stewart, Sarah J Welsh, et al.
Cancer Discovery
|
July 12, 2022
AACR Project GENIE: 100,000 Cases and Beyond
Trevor J Pugh, Jonathan L Bell, Jeff P Bruce, et al.
Aging Cell
|
April 2, 2020
Galacto-conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity
Estela González-Gualda, Marta Pàez-Ribes, Beatriz Lozano-Torres, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 38) with videos related to
Sort By:
Page
of 4
Current Problems in Cancer
|
January 19, 2021
Response to BRAF and MEK1/2 inhibition in a young adult with BRAF V600E mutant epithelioid glioblastoma multiforme: A Case Report and Literature Review
Ashwin Venkatesh, Amol Joshi, Kieren Allinson, et al.
Plos One
|
January 4, 2013
Bin2 is a membrane sculpting N-BAR protein that influences leucocyte podosomes, motility and phagocytosis
María José Sánchez-Barrena, Yvonne Vallis, Menna R Clatworthy, et al.
Trends in Cancer
|
June 5, 2024
Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer
Chris Abbosh, Darren Hodgson, Gary J Doherty, et al.
Journal for Immunotherapy of Cancer
|
May 30, 2025
Differential safety profiles of durvalumab monotherapy and durvalumab in combination with tremelimumab in adult patients with advanced cancers
Claire Morgan, John Kurland, Mayur Patel, et al.
Iscience
|
September 9, 2024
Machine learning modeling of patient health signals informs long-term survival on immune checkpoint inhibitor therapy
Gerald J Sun, Gustavo Arango-Argoty, Gary J Doherty, et al.
British Journal of Clinical Pharmacology
|
November 12, 2025
Population pharmacokinetics and exposure-response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study
Xiaoying Zhao, Junjie Ding, Jiajia Zhao, et al.
Genes & Development
|
August 10, 2017
Lung tumors with distinct p53 mutations respond similarly to p53 targeted therapy but exhibit genotype-specific statin sensitivity
Frances K Turrell, Emma M Kerr, Meiling Gao, et al.
BMC Cancer
|
January 25, 2022
The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy
Nicola A Thompson, Grant D Stewart, Sarah J Welsh, et al.
Cancer Discovery
|
July 12, 2022
AACR Project GENIE: 100,000 Cases and Beyond
Trevor J Pugh, Jonathan L Bell, Jeff P Bruce, et al.
Aging Cell
|
April 2, 2020
Galacto-conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity
Estela González-Gualda, Marta Pàez-Ribes, Beatriz Lozano-Torres, et al.
Page
of 4